Development for new cancer vaccine against heterogenicity and HLA-loss of tumor

点击翻译按钮获取中文摘要

Recently, cancer vaccine using epitope peptides was performed all over the world. Epitope peptides induced the strong cytotoxic T lymphocytes (CTL) in cancer patients, therefore clinical trials of cancer vaccine were performed. However, the outcome of clinical trial has not so excellent. One of the reasons was due to the heterogenicity and HLA-loss of the tumor. To overcome these problems, we focused on the tumor angiogenesis and examined the immunogenicity for tumor-angiogenesis related targets.In this study, we have determined the immunogenicity from these targets. We have determined epitope peptides restricted to HLA-A^*2402 which was the most common in Japanese. These findings may suggest that tumor-angiogenesis related targets are excellent targets to improve the clinical efficacy of cancer vaccine.